New York, January 16, 2026, 05:00 (EST) — Premarket
ImmunityBio, Inc. shares jumped roughly 32% to $3.95 in premarket trading Friday following the biotech’s report of a steep rise in preliminary 2025 product revenue. The company also highlighted recent regulatory approvals in Saudi Arabia.
The update offers investors an early glimpse of how quickly ANKTIVA is growing commercially, ahead of the company’s audited annual results. It also provides fresh figures tied to the company’s expansion into new markets—the section traders have been eager to scrutinize in the filings.
ImmunityBio reported preliminary net product revenue of roughly $38.3 million for the quarter ending Dec. 31, marking a 20% rise from the previous quarter and a staggering 431% jump compared to the same period last year. For the full year, preliminary net product revenue hit about $113.0 million, which the company called an approximate 700% increase year over year.
The company wrapped up the quarter with roughly $242.8 million in cash, cash equivalents, and marketable securities on hand. CEO Richard Adcock highlighted “strong quarter-over-quarter revenue growth,” driven by faster adoption of ANKTIVA and the ongoing rollout of their commercial strategy. Business Wire
A Form 8-K filed Thursday noted the figures are preliminary and unaudited, warning the final numbers in the annual report might change. The filing also stated the press release was included as an exhibit.
Saudi Arabia offered a near-term boost. On Jan. 14, the Saudi Food and Drug Authority gave accelerated approval to ANKTIVA, paired with checkpoint inhibitors, for treating metastatic non-small cell lung cancer, the company announced.
On Jan. 14, the company announced that the same regulator gave the green light to ANKTIVA plus BCG — a bacteria-based therapy targeting the bladder — for select patients with BCG-unresponsive non-muscle invasive bladder cancer, an early-stage form of the disease.
ImmunityBio announced plans to open a regional office in Saudi Arabia and named Biopharma Cigalah as its commercial and distribution partner for the Middle East and North Africa.
The bladder cancer update included key near-term goals. The company aims to complete enrollment in a randomized trial for BCG-naive patients by Q2 2026, with a BLA — a U.S. biologics licensing application — planned by year-end.
ImmunityBio said the accelerated approval for lung cancer rests on clinical data from two studies, with a confirmatory randomized trial, ResQ 201A, now recruiting. Founder Patrick Soon-Shiong noted, “This approval also represents the first authorization for subcutaneous administration of ANKTIVA.” Business Wire
There are some caveats. The company noted the revenue numbers remain subject to closing procedures. Plus, overseas approvals still need to turn into actual sales, pricing agreements, and reimbursement in the new markets. Confirmatory studies are also ongoing.
Investors are now watching to see if the premarket surge sticks once regular trading begins, alongside the upcoming audited update in the annual report. Looking ahead, the timeline highlights trial enrollment expected by Q2 2026, plus any new regulatory filings linked to the company’s “year-end” goal. Business Wire
